Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 11385 - 11392 of 12007 results
Termination of Employee Based on her Marriage to an Undocumented Alien Does Not Violate Title VII
May 30, 2012| Blog| Viewpoint
ICANN's Appoints Independent Objector and Gets TLD Application System Back Online
May 29, 2012| Blog| Viewpoint
Keeping the Whistle Away from the Whistleblower
May 24, 2012| Blog| Viewpoint
Does an employer invade an employee’s privacy by accessing and reviewing the employee’s email?
May 23, 2012| Blog| Viewpoint
FTC v. Myspace Part II -- The Takeaways
May 23, 2012| Blog| Viewpoint
Sellers Prepare: Health Care Due Diligence
May 23, 2012| Blog| Viewpoint
No Expectation of Privacy in Emails Sent Over Employer's Email Account, Massachusetts Court Decides
May 21, 2012| Blog| Viewpoint
HIPAA Criminal Penalties – Defendant May Be Found Guilty without “Knowledge” That Acts Are Illegal
May 21, 2012| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|